Coya Therapeutics Inc

COYANASDAQ · USD
3.02USD0.00 (+0.67%)
122

Coya Therapeutics Inc (COYA) Covered Calls

Coya Therapeutics Inc trades in the Biotechnology industry with an IV Rank of 82.94%, high versus the past year. COYA's highest covered call setup is the $5.00 strike expiring May 21, 2027, sorted by theoretical annualized return. It's 66.67% out of the money with 186 days to expiration, a 68.33% return until expiration, and a 134.09% theoretical annualized return. Across the setups shown, annualized returns run from 134.09% to 134.09% at strikes between $5.00 and $5.00, with 186 to 186 days to expiration, as of Nov 16, 2026.

Read more

Running COYA covered calls helps you generate income from Coya Therapeutics Inc shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best COYA covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.

A covered call pairs limited risk with a clear income profile. If COYA stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling COYA covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given COYA covered call is worth writing.

Coya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a Treg-enhancing biologic for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous and/or intravenous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases.

2027-05-211865.0066.670.054.90205.0068.33134.09-1.67+0.91114.85

As of Nov 16, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →

Stock Statistics

  • IndustryBiotechnology
  • SectorHealthcare
  • IV Rank82.94% High
  • Market cap (M$)71
  • 52 weeks high-54.38%
  • 52 weeks low11.03%
  • Analyst recommendationStrong Buy
    1.00
  • Target price$15.21
    403.64% above the current stock price
  • Dividend—
  • Payout ratio—
  • Earnings date2026-11-10
  • P/E—
  • Future P/E—
  • EPS (ttm)-1.33
  • EPS growth next 5 years2.56%

As of Nov 16, 2026